Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen
- 20 July 2007
- Vol. 25 (29) , 5343-5347
- https://doi.org/10.1016/j.vaccine.2007.05.007
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Montanide® ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulationsVaccine, 2005
- CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II StudyJournal of Clinical Immunology, 2004
- Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine responseVaccine, 2004
- Use of CpG oligodeoxynucleotides as immune adjuvantsImmunological Reviews, 2004
- Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccineVaccine, 2004
- Biochemical and Immunological Characterization of Bacterially Expressed and RefoldedPlasmodium falciparum42-Kilodalton C-Terminal Merozoite Surface Protein 1Infection and Immunity, 2003
- In Vitro Studies with RecombinantPlasmodium falciparumApical Membrane Antigen 1 (AMA1): Production and Activity of an AMA1 Vaccine and Generation of a Multiallelic ResponseInfection and Immunity, 2002
- Conjugation of protein to immunostimulatory DNA results in a rapid, long‐lasting and potent induction of cell‐mediated and humoral immunityEuropean Journal of Immunology, 2000
- Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In VivoThe Journal of Immunology, 2000
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995